The pharmaceutical industries are far from philanthropic enterprises. Their financial health is far more important to them than the health of consumers, and the drugs that do have marketing approval are currently pure commercial products listed on the stock market.

From a financial and stock market point of view, the pharmaceutical industry ranks directly after the banking and oil industries.

On the stock market, a large American pharmaceutical company alone represents 3 times Boeing, 7 times EADS (Airbus group: European Aeronautic Defence and Space company).

The 20% annual profit of these companies is higher than that of Total.

Obviously, famous budgets are needed to pay "consulting" physicians and to continuously invest in research for "new" drugs.

In France, there are about 50 doctors under contract. They range from 20,000 to 200 or 300,000 € per year.

Research and development of a new drug requires 800 million euros.

These contracted physicians participate in clinical trials that are ALL falsified at every stage (according to Philippe Even).

The industry makes these physicians sign off on articles and clinical trials that they have not conducted themselves. They affix their signature.

It is therefore understandable that all clinical trials are falsified at all stages, because no commercial company is going to invest such sums of money to announce in the end that the product does not work!

This is how :

• are excluded from these studies, all "at risk" patients who could have an accident (even independent of the trial drug), this means that the
• we select only patients who correspond to a very precise profile whereas the results obtained will be generalized to the whole population...
• we hide the accidents that occur

Then the industry organizes congresses, 12,000 per year on the planet. It chooses the themes, the chairpersons and the rapporteurs (its spokespersons). Then, the articles appear in the press and are relayed by the media.

The current lack of innovation must obviously be compensated for financially.

Therefore, to promote the qualities of the products, the industry invests twice as much in marketing as in research.

To develop this marketing, manufacturers invest about €25,000 per doctor per year.

In France in 2007, a doctor saw an average of 333 medical representatives per year, ¾ of whom were women.

Another solution is put in place to increase laboratory revenues, expand the scope of prescriptions...

When markets are reduced, the industry expands the scope of prescribing by changing the criteria for prescribing drugs and lowering the standards for blood draws, for example.

Let's take the example of hypertension. In the 1980s, people treated for hypertension were those who were above 17 or 18. Subsequently, the curves are manipulated and it is demonstrated that the lower the blood pressure, the fewer vascular accidents there are, which is statistically false.

The French National Authority for Health (HAS), in collaboration with the laboratories, then decided to lower the prescription criteria to 16-15, which quadrupled the market for the sale of antihypertensive drugs.

Currently, the HAS recommends preventive treatment of 13 or 14 year olds...

This same process was applied to osteoporosis, for which osteopenia was invented, to diabetes, for which we speak of pre-diabetes, and to cholesterol, for which the standards have been lowered and which is now treated preventively in order to avoid strokes.

This type of technique opens up huge markets

According to Professor Philippe Even, only 25% of drugs would be indispensable, 25% would be occasionally useful in certain patients, 25% have no scientifically proven efficacy, and the remaining 25% have none.

Currently in France, 75% of them are reimbursed...

So find out what your doctor prescribes... the best thing is to do without both the doctor, and medications and replace them with very effective natural and alternative solutions.